Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
Clinical and Translational Medicine · 2025-09 · 15 (9)
DOI: 10.1002/ctm2.70472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 05.09.2025. Verfasst von Agnieszka Beata Malczewski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Icon Cancer Centre, Wesley and South Brisbane, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Queensland Children's Hospital Foundation.
Abstract (Originalsprache)
Checkpoint inhibitor therapy is the most common type of immunotherapy used in the clinical setting, however, there are significant obstacles with treatment resistance and cancer progression. Since its introduction, there have been relatively few advances in the development of prognostic or predictive biomarkers. The field of metabolomics studies small molecules and can provide us with an understanding of the dynamic events evolving during the tumour‐drug‐immune‐system interaction. Several key pathways have emerged as important in understanding resistance mechanisms thereby providing a rationale for targeting immunometabolism in order to enhance the immune response during checkpoint inhibitor therapy. In the first part of this review, we explore the role of gut microbiome‐derived short‐chain fatty acids, which are recognized as important immunoregulatory molecules shaping T‐cell activation, effector and memory function. We then discuss tryptophan catabolism as a key predictor of primary checkpoint inhibitor failure. Lastly, we focus on immunometabolism as an important future target in immunotherapy. One sentence summary This review focusses on microbiome‐derived metabolites and their role in immunometabolism and the enhancement of checkpoint inhibitor responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icon Cancer Centre, Wesley and South Brisbane, Brisbane, Queensland, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Science and Technology, University of New England, Armidale, New South Wales, Australia.
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID-Profile: Severine Navarro
Förderung
- Queensland Children's Hospital Foundation
Zitieren
APA
Malczewski, A. B., Coward, J. I., Ketheesan, N., & Navarro, S. (2025). Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy. Clinical and Translational Medicine, 15(9). https://doi.org/10.1002/ctm2.70472
Vancouver
Malczewski AB, Coward JI, Ketheesan N, Navarro S. Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy. Clinical and Translational Medicine. 2025;15(9). doi:10.1002/ctm2.70472
BibTeX
@article{Malczewski2025,
author = {Malczewski, Agnieszka Beata and Coward, Jermaine Ig and Ketheesan, Natkunam and Navarro, Severine},
title = {Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy},
journal = {Clinical and Translational Medicine},
year = {2025},
volume = {15},
number = {9},
doi = {10.1002/ctm2.70472}
}
EUVIMED